TKG Therapeutics develops cancer immunotherapy drugs utilizing hairpin-shaped nucleic acid and miRNA that is overexpressed in cancer cells to trigger innate immunity. This approach enables the targeted destruction of cancer cells, enhancing patients' immune responses against specific carcinogenic substances.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MGUCFounders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic toxicity and damage to healthy tissues. Traditional chemotherapies and radiotherapies can cause severe side effects, reducing the patient's quality of life and limiting the effectiveness of the treatment. There is a need for more targeted therapies that selectively destroy cancer cells while sparing normal cells.
Solution
TKG Therapeutics is developing cancer immunotherapies that utilize hairpin-shaped nucleic acids and microRNAs (miRNAs) overexpressed in cancer cells to trigger innate immunity. This approach enables the targeted destruction of cancer cells by selectively activating the immune system within the tumor microenvironment. By targeting specific genetic markers unique to cancer cells, TKG's therapies aim to minimize off-target effects and enhance the patient's immune response against carcinogenic substances. The technology seeks to improve treatment efficacy and reduce the adverse side effects associated with conventional cancer therapies.
Target Audience
The primary target audience includes cancer patients, oncologists, and researchers seeking more effective and less toxic cancer treatment options.
Features
- Utilizes hairpin-shaped nucleic acids and miRNAs to target cancer cells
- Activates innate immunity selectively within the tumor microenvironment
- Designed to minimize off-target effects and systemic toxicity
- Enhances the patient's immune response against specific carcinogenic substances